SCN2A: The FamilieSCN2A Foundation is excited to announce that one $61,068 grant is available for research to accelerate the development of therapeutic treatments and disease-modifying advancements for those living with autism and/or epilepsy due to changes in the SCN2A gene. We are interested in funding work that advances understanding of the cellular, molecular, genetic, and systems-level mechanisms of SCN2A-related disorders. hopes Specific areas of interest include but are not limited to:

1. Investigating de-risked drugs as treatment for SCN2A-related disorders (ie. repurposing FDA-approved drugs or investigating non-approved "shelved" drugs but with validated clinical safety profiles)
2. Understanding the prevalence of SCN2A-related disorders in the population
3. Patient level functional analysis on all variants / genotype-phenotype assessment.

Priority will be given to innovative projects which could potentially lead to therapeutic treatments or cures for those with SCN2A-related disorders.

In addition, applicants are encouraged to collaborate with existing SCN2A researchers and to leverage existing disease models and data (e.g. animal models, Simons Searchlight registry and biobank, CTRS, Ciitizen/Invitae data.)